Traumatic Brain Injury Clinical Trial
Official title:
Evaluating the Use of Eye-tracking Technology in the Diagnosis of Neurological Patients, Including Patients With Reduced Consciousness
Verified date | July 2023 |
Source | AssisTech Sp. z o.o. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Demonstrating that diagnostics of the state of consciousness and cognitive functions of patients with consciousness disorders performed using C-Eye X (based on eye-tracking technology) allows a more objective assessment of state of patients who were wrongly diagnosed based on popular methods using in a clinical practice (like behavioural scales on paper forms).
Status | Completed |
Enrollment | 90 |
Est. completion date | March 31, 2023 |
Est. primary completion date | January 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Completed 18 years of age. 2. Consent of the legal guardian to participate in the Study and access to medical records. 3. Medical diagnosis indicating damage to the central nervous system. 4. Having and sharing a description of imaging tests (alternatively MRI - Magnetic Resonance Imaging or CT - Computed Tomography) and (alternatively) ophthalmoscopy, ophthalmology, auditory tests. 5. Presentation of a list of medications used by the patient that may affect the results obtained in tests of cognitive function. 6. Acceptance by a physician (e.g. neurologist, neurosurgeon, internist) to participate in a clinical trial, taken after reviewing the Study protocol, including there is a need to take into account: 1. the ability to communicate only by sight (no verbal, sign or other communication), 2. the absence of dementia and aphasic disorders before the event that led to CNS damage and the patient's current condition, 3. preserved at least one functioning eyeball (possibility of cooperation with an eye tracker). Exclusion Criteria: 1. Visual defect (refractive defect) diagnosed before the incident, requiring work with glasses with lenses of more than ±3 diopters. 2. Inclusion of drug treatment during the Study (observation), which can affect the patient's cognitive functioning (both in terms of cognitive enhancement and impairment/dementia). |
Country | Name | City | State |
---|---|---|---|
Poland | Care and Rehabilitation Center "HEALTH" ("ZDROWIE") | Czestochowa | |
Poland | Polish Center for Functional Rehabilitation VOTUM | Kraków | |
Poland | Polish Center for Functional Rehabilitation SAWIMED | Sawice | |
Poland | Neurorehabilitation Center of Dr. Roman Olejniczak | Wroclaw | |
Poland | County Hospital | Zawiercie |
Lead Sponsor | Collaborator |
---|---|
AssisTech Sp. z o.o. |
Poland,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Test 1: Minimally Conscious State Detection (MCSD Test) | The Test 1 consist of 6 subscales (including 11 points):
Auditory sensitivity Visual functions Auditory-visual integration Command execution Autopsychic orientation Pressure localisation test The MCSD Test is performed in 5 trials during 14 days of observation with intervals of at least one day between test repetitions. The result of the completed test is an indicator of one of the following states of the patient's condition diagnosis: UWS MCS - MCS + |
14 days | |
Primary | Test 2: Cognitive Function Assessment (CFA Test) | The Test 2 consist of 6 subscales (including 24 points):
Attention Language functions Visual-spatial functions Autopsychic orientation Memory Abstract thinking The total number of points that a patient can obtain in a single trial for performing tasks in the CFA test is 24 points. The CFA Test is performed in 3 trials during 14 days at intervals of at least one day. For the CFA test, the results will be presented as: the sum of scores for all subscales of the test, the point value obtained in each subscale, the percentage of the total score for all subscales of the test related to the maximum value possible for the test - 24 points the percentage value in each subscale related to the maximum value possible in the subscale. The result obtained: ______ - ____% ______ - ____% ______ - ____% Total score = ____% Scale: 0 - 100% |
14 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03052712 -
Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies
|
N/A | |
Recruiting |
NCT05503316 -
The Roll of Balance Confidence in Gait Rehabilitation in Persons With a Lesion of the Central Nervous System
|
N/A | |
Completed |
NCT04356963 -
Adjunct VR Pain Management in Acute Brain Injury
|
N/A | |
Completed |
NCT03418129 -
Neuromodulatory Treatments for Pain Management in TBI
|
N/A | |
Terminated |
NCT03698747 -
Myelin Imaging in Concussed High School Football Players
|
||
Recruiting |
NCT05130658 -
Study to Improve Ambulation in Individuals With TBI Using Virtual Reality -Based Treadmill Training
|
N/A | |
Recruiting |
NCT04560946 -
Personalized, Augmented Cognitive Training (PACT) for Service Members and Veterans With a History of TBI
|
N/A | |
Completed |
NCT05160194 -
Gaining Real-Life Skills Over the Web
|
N/A | |
Recruiting |
NCT02059941 -
Managing Severe Traumatic Brain Injury (TBI) Without Intracranial Pressure Monitoring (ICP) Monitoring Guidelines
|
N/A | |
Recruiting |
NCT03940443 -
Differences in Mortality and Morbidity in Patients Suffering a Time-critical Condition Between GEMS and HEMS
|
||
Recruiting |
NCT03937947 -
Traumatic Brain Injury Associated Radiological DVT Incidence and Significance Study
|
||
Completed |
NCT04465019 -
Exoskeleton Rehabilitation on TBI
|
||
Recruiting |
NCT04530955 -
Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)
|
N/A | |
Recruiting |
NCT03899532 -
Remote Ischemic Conditioning in Traumatic Brain Injury
|
N/A | |
Suspended |
NCT04244058 -
Changes in Glutamatergic Neurotransmission of Severe TBI Patients
|
Early Phase 1 | |
Completed |
NCT03307070 -
Adapted Cognitive Behavioral Treatment for Depression in Patients With Moderate to Severe Traumatic Brain Injury
|
N/A | |
Recruiting |
NCT04274777 -
The Relationship Between Lipid Peroxidation Products From Traumatic Brain Injury and Secondary Coagulation Disorders
|
||
Withdrawn |
NCT05062148 -
Fundamental and Applied Concussion Recovery Modality Research and Development: Applications for the Enhanced Recovery
|
N/A | |
Withdrawn |
NCT04199130 -
Cognitive Rehabilitation and Brain Activity of Attention-Control Impairment in TBI
|
N/A | |
Withdrawn |
NCT03626727 -
Evaluation of the Efficacy of Sodium Oxybate (Xyrem®) in Treatment of Post-traumatic Narcolepsy and Post-traumatic Hypersomnia
|
Early Phase 1 |